International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
Authors
Glucocorticoids taken orally increase the risk of fractures. It has been noted that a dose as low as 2.5 mg/day increases the risk of vertebral fracture. What is less clear is the possible influence of other risk factors for osteoporosis on the presence of non-vertebral fractures in patients taking glucocorticoids.
A cross-sectional study, performed on 513 men and women from Spain, who were taking at least 7.5 mg/day of oral prednisone for a minimum of 3 months. A questionnaire was developed, through which information on risk factors was collected.
A cross-sectional study, performed on 513 men and women from Spain, who were taking at least 7.5 mg/day of oral prednisone for a minimum of 3 months. A questionnaire was developed, through which information on risk factors was collected.
28.3% of the patients who were taking glucocorticoids at a daily oral dose of 7.5 mg/day for a minimum of 3 months had suffered at least one non-vertebral fracture. The risk increased with age, the number of months the glucocorticoids had been taken, the presence of falls in the last year and, above all, with a maternal history of hip fracture.
In patients taking oral glucocorticoids for over 3 months at doses higher than 7.5 mg/day of prednisone or equivalent, the prevalence of non-vertebral fractures was 28.3%. Some risk factors associated with the presence of these fractures were identified. The duration of glucocorticoid use appears to be more strongly related to the presence of non-vertebral fractures than the daily dose.
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Reynolds AW, Liu G, Kocis PT, Skowronski JN, Leslie DL, et al. Comparison of Osteoporosis Pharmacotherapy Fracture Rates: Analysis of a MarketScan® Claims Database Cohort. Int J Endocrinol Metab. 2018;16(3):e12104. doi: https://doi.org/10.5812/ijem.12104
Aoyagi J, Kanai T, Ito T, Odaka J, Saito T, et al. The Effects of Glucocorticoids on Bone Strength in Children with Renal Diseases. J Compr Ped. 2016;7(4):e38727. doi: https://doi.org/10.17795/compreped-38727
Najafi S, Rezasoltani Z, Azma K, Nayeb Abbas S, Aghaei M, et al. Efficacy of Oral Alendronate Versus Zoledronic Acid on Postmenopausal Osteoporosis. Ann Mil Health Sci Res. 2019;17(2):e86960. doi: https://doi.org/10.5812/amh.86960
Mowla K. TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS: SODIUM FLUORIDE OR CALCITONIN. Jundishapur J Nat Pharm Prod. 2006;1(1):e74294. doi:
Javadi E, Hossein-nezhad A, Khalili-Fard A, Adibi H, Maghbooli J, et al. Correlation between bone mineral density and osteoporosis With Ca and vitamin D intake. Zahedan J Res Med Sci. 2003;5(1):e95137. doi:
More by these authors
Last Update: 3 weeks ago
Last Update: 3 weeks ago
Last Update: 3 weeks ago
Last Update: 1 day ago